Sage intends to present detailed results from the STATUS Trial at an upcoming medical meeting ... "Risk Factors" in our most recent Quarterly Report on Form 10-Q, as well as discussions of ...

The trial, which enrolled 147 participants, was designed to study the dose-response relationship of different doses of SAGE-324 for upper limb tremor for a three-month treatment period.

Sage Therapeutics has slightly tweaked the primary endpoint for a phase 3 trial of the Biogen-partnered ... the change in its third-quarter earnings report Tuesday. RBC Capital Markets said ...